Failure Of Short-Term Cd4-Pe40 Infusions To Reduce Virus Load In Human Immunodeficiency Virus-Infected Persons
| Autor: | Rani V. Ramachandran, Donald H. Batts, Robin Wood, Thomas C. Merigan, David Katzenstein |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
CD4-Positive T-Lymphocytes Virulence Factors Lymphocyte Bacterial Toxins Exotoxins Biology Peripheral blood mononuclear cell Drug Administration Schedule law.invention Proviruses In vivo law HIV Seropositivity medicine Humans Immunology and Allergy Pseudomonas exotoxin Treatment Failure Infusions Intravenous ADP Ribose Transferases Immunotoxins Immunogenicity HIV Virology Infectious Diseases medicine.anatomical_structure CD4 Antigens DNA Viral Pseudomonas aeruginosa Toxicity Human Immunodeficiency Virus DNA Recombinant DNA RNA Viral |
| Zdroj: | Journal of Infectious Diseases. 170:1009-1013 |
| ISSN: | 1537-6613 0022-1899 |
| DOI: | 10.1093/infdis/170.4.1009 |
| Popis: | The safety, immunologic, and antiviral effects of a recombinant biologic product that combines the second and third domains of the CD4 molecule and Pseudomonas exotoxin A (PE40) were evaluated in 21 human immunodeficiency virus (HIV)-infected subjects in a phase III open-label dose-ranging study. Subjects with CD4+ lymphocyte counts of 100-500/mm3 received CD4-PE40 at 40, 80, or 160 micrograms/m2 by infusion three to seven times over 10 days. At the maximum tolerated dose (80 micrograms/m2), peak CD4-PE40 levels were 65-130 ng/mL with a serum half-life of 3.6 +/- 1.5 h. Toxicity, primarily increased hepatic transaminases, was dose-related and reversible. HIV DNA proviral levels in peripheral blood mononuclear cells and plasma HIV RNA remained stable during and after CD4-PE40 infusions. The relative resistance of clinical isolates of HIV, limits of the tolerated dose, and the immunogenicity and short half-life of the protein may explain the lack of in vivo antiviral effect of CD4-PE40. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|